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Articles
Diagnostic accuracy of whole-body MRI versus standard 
imaging pathways for metastatic disease in newly diagnosed 
colorectal cancer: the prospective Streamline C trial
Stuart A Taylor, Sue Mallett, Sandy Beare, Gauraang Bhatnagar, Dominic Blunt, Peter Boavida, John Bridgewater, Caroline S Clarke, Marian Duggan, 
Steve Ellis, Robert Glynne-Jones, Vicky Goh, Ashley M Groves, Ayshea Hameeduddin, Sam M Janes, Edward W Johnston, Dow-Mu Koh, Anne Miles, 
Stephen Morris, Alison Morton, Neal Navani, John O’Donohue, Alfred Oliver, Anwar R Padhani, Helen Pardoe, Uday Patel, Shonit Punwani, 
Laura Quinn, Hameed Rafiee, Krystyna Reczko, Andrea G Rockall, Khawaja Shahabuddin, Harbir S Sidhu, Jonathan Teague, Mohamed A Thaha, 
Matthew Train, Katherine van Ree, Sanjaya Wijeyekoon, Steve Halligan, on behalf of the Streamline investigators*
Summary
Background Whole-body MRI (WB-MRI) could be an alternative to multimodality staging of colorectal cancer, but its 
diagnostic accuracy, effect on staging times, number of tests needed, cost, and effect on treatment decisions are 
unknown. We aimed to prospectively compare the diagnostic accuracy and efficiency of WB-MRI-based staging 
pathways with standard pathways in colorectal cancer.
Methods The Streamline C trial was a prospective, multicentre trial done in 16 hospitals in England. Eligible patients 
were 18 years or older, with newly diagnosed colorectal cancer. Exclusion criteria were severe systemic disease, 
pregnancy, contraindications to MRI, or polyp cancer. Patients underwent WB-MRI, the result of which was withheld 
until standard staging investigations were complete and the first treatment decision made. The multidisciplinary 
team recorded its treatment decision based on standard investigations, then on the WB-MRI staging pathway 
(WB-MRI plus additional tests generated), and finally on all tests. The primary outcome was difference in per-patient 
sensitivity for metastases between standard and WB-MRI staging pathways against a consensus reference standard at 
12 months, in the per-protocol population. Secondary outcomes were difference in per-patient specificity for metastatic 
disease detection between standard and WB-MRI staging pathways, differences in treatment decisions, staging 
efficiency (time taken, test number, and costs), and per-organ sensitivity and specificity for metastases and per-patient 
agreement for local T and N stage. This trial is registered with the International Standard Randomised Controlled 
Trial registry, number ISRCTN43958015, and is complete.
Findings Between March 26, 2013, and Aug 19, 2016, 1020 patients were screened for eligibility. 370 patients were 
recruited, 299 of whom completed the trial; 68 (23%) had metastasis at baseline. Pathway sensitivity was 67% (95% CI 
56 to 78) for WB-MRI and 63% (51 to 74) for standard pathways, a difference in sensitivity of 4% (–5 to 13, p=0·51). 
No adverse events related to imaging were reported. Specificity did not differ between WB-MRI (95% [95% CI 92–97]) 
and standard pathways (93% [90–96], p=0·48). Agreement with the multidisciplinary team’s final treatment decision was 
96% for WB-MRI and 95% for the standard pathway. Time to complete staging was shorter for WB-MRI (median, 8 days 
[IQR 6–9]) than for the standard pathway (13 days [11–15]); a 5-day (3–7) difference. WB-MRI required fewer tests (median, 
one [95% CI 1 to 1]) than did standard pathways (two [2 to 2]), a difference of one (1 to 1). Mean per-patient staging costs 
were £216 (95% CI 211–221) for WB-MRI and £285 (260–310) for standard pathways.
Interpretation WB-MRI staging pathways have similar accuracy to standard pathways and reduce the number of tests 
needed, staging time, and cost.
Funding UK National Institute for Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Colorectal cancer is the second leading cause of cancer-
related deaths in the UK, with about 16 000 deaths 
annually.1 Accurate staging is fundamental for optimal 
patient outcomes, particularly identification of metastatic 
disease, because this typically dictates therapeutic 
strategy. Up to 50% of patients with metastatic disease 
relapse after apparently curative surgery.2 Upfront 
detection of metastases would allow appropriate use of 
chemotherapeutic, surgical, and ablative therapies.3
Staging pathways are complex, relying on high 
technology imaging platforms such as CT, PET-CT, and 
MRI. In England, for example, the National Institute for 
Health and Care Excellence (NICE) publishes guidelines 
that require multiple, sequential imaging tests to 
complete staging and allow the first treatment decisions 
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to be made.4 The complexity of staging pathways is due to 
modalities having variable accuracies across organs at 
risk for harbouring metastases. Standard pathways are, 
therefore, time and resource intensive, irradiate patients,5 
and increase anxiety if they are protracted.6
Modern MRI scanners can image the entire body within 
1 h, and whole-body MRI (WB-MRI)—which typically 
scans from the head to mid-thigh—is a potentially more 
accurate and safer alternative to standard multimodality 
staging pathways. WB-MRI could also accelerate staging, 
thereby increasing efficiency by reducing additional tests, 
staging time, and costs. Meta-analyses suggest accuracy 
for metastatic disease is equivalent to, or might exceed, 
standard technologies,7–18 but most combine disparate 
cancers7–9,11,12,14,15 or focus on metastasis detection in a single 
organ,10,13,16–18 or both. No meta-analysis has considered 
colorectal cancer staging in isolation; the largest primary 
study to date included only 20 patients.19 Primary studies 
are predominantly small, single site, explanatory studies 
with WB-MRI interpretation by a few highly experienced 
radiologists, which is unlike real-world pathways.20 Studies 
usually compare single modalities (eg, WB-MRI vs 
PET-CT) instead of the multiple staging tests encountered 
in daily practice.20 There are no data regarding how 
WB-MRI pathways influence staging times, additional 
tests, costs, or treatment decisions. As such, there is 
insufficient evid ence to assess whether WB-MRI should be 
adopted.21
We did two parallel prospective multicentre trials to 
elucidate and directly compare the diagnostic accuracy 
and efficiency of WB-MRI-based staging pathways with 
standard pathways in non-small-cell lung cancer 
(Streamline L)22 and colorectal cancer (Streamline C). 
Here, we report findings from Streamline C.
Methods
Study design and participants
Streamline C is a multicentre, prospective trial com-
paring diagnostic accuracy for metastatic disease of 
staging pathways based on initial WB-MRI, with standard 
pathways in colorectal cancer. Ethics committee approval 
was granted on Oct 3, 2012, and the trial was coordinated 
by Cancer Research UK and University College London 
Cancer Trials Centre, with oversight from an independent 
data monitoring committee and a trial steering 
committee. All patients gave written informed consent.
Patients were recruited from 16 general and teaching 
UK National Health Service (NHS) hospitals in England. 
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Research in context
Evidence before this study
The detection of metastatic disease during colon cancer 
staging underpins treatment strategy and is fundamental to 
the optimisation of patient outcomes. Staging pathways rely 
on high technology imaging platforms such as CT, PET-CT, and 
MRI, which differ in their diagnostic accuracies across 
individual organs. Such multimodality staging pathways are 
complex, resource and time intensive, involve irradiation, and 
increase patient anxiety. Modern MRI platforms can image the 
whole body within 1 h, and whole-body MRI (WB-MRI) is 
advocated as a more accurate, efficient, and safer alternative 
to multimodality staging pathways. We searched PubMed and 
Embase (without language restriction) for articles published 
between Jan 1, 1990, and Sept 30, 2018, using MeSH and 
full-text search-strings for “cancer”, “neoplasm” “staging”, 
“diagnostic accuracy”, “magnetic resonance imaging”, 
“whole body imaging”, “diffusion magnetic resonance 
imaging”, “metastasis”, “colorectal”, and “colon”. We found 
several meta-analyses reporting WB-MRI accuracy for cancer 
staging. Many combined different primary cancers in single 
analyses or were limited to detecting metastasis in single organs 
(or both). Most meta-analyses compared WB-MRI with PET-CT, 
and scintigraphy (in the case of bone metastasis), rather than CT 
alone, which is the test used most commonly in colorectal 
cancer staging. No meta-analysis considered colorectal cancer in 
isolation. Most primary studies were small, single site, and 
explanatory, with WB-MRI interpreted by a few specialised 
radiologists. They focused on single modality comparisons 
rather than evaluating real-world, multimodality staging 
pathways. We found no data regarding how WB-MRI influences 
the first major treatment decision or staging efficiency.
Added value of this study
To our knowledge, this is the largest prospective multicentre 
trial to date comparing the diagnostic accuracy of WB-MRI 
staging pathways to standard staging in patients newly 
diagnosed with colorectal cancer. We used a pragmatic trial 
design to better test pathway performance in routine clinical 
practice and investigated pathway efficiency in terms of test 
number, time to completion, and costs. We also 
contemporaneously tested the effect of alternative staging 
pathways on the nature and timing of the first major treatment 
decisions. Patient outcomes were followed up after 12 months 
to better evaluate pathway accuracy at the time of initial 
staging. We found both pathways had similar accuracies for 
identifying patients with metastatic disease and the nature of 
first major treatment decision was similar. Notably, WB-MRI 
was more efficient and reduced the number of tests needed, 
time to complete staging, and costs.
Implications of all the available evidence
WB-MRI staging pathways have similar accuracy to current 
standard staging pathways, resulting in the same treatment 
decisions. However, they are more efficient and reduce test 
numbers, time to complete staging, and costs. WB-MRI is, 
therefore, more suitable for staging in routine clinical practice. 
Future research should investigate the use of WB-MRI 
treatment response assessment and cancer surveillance after 
curative treatments.
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Because eight of the 16 sites did not have the infrastructure 
to do WB-MRI, these sites sent patients to a nearby 
hospital for scanning (appendix p 2). Eligible patients 
were aged 18 years or older with histologically proven or 
suspected colorectal cancer, referred for staging. Suspicion 
of colorectal cancer was defined as the presence of a mass 
on endoscopy or imaging (or both), triggering staging 
investigations; those without a final diagnosis of cancer 
were subsequently excluded. Patients were in eligible if 
they could not provide informed consent, had severe 
systemic disease making it undesirable to participate, 
were pregnant, had contraindications to MRI, or had a 
polyp cancer.
Participants were identified from outpatient clinics, 
multidisciplinary team meetings, and inpatient wards by 
the local research team, who took informed consent from 
consecutive, unselected, eligible patients. A screening 
log detailed all patients approached and reasons for non-
participation, where applicable. Age, performance status, 
sex, and request date for the first staging investigation 
were collected from recruited patients. Staging com-
pletion date was also recorded, defined as the date of the 
final test in the standard staging pathway.
The protocol has been published20 and is available 
online.
Procedures
Participants had contemporaneous WB-MRI plus all 
standard staging investigations done as part of usual 
clinical care. Standard investigations were generally 
undertaken at the recruitment site, or a secondary 
hospital by referral in the case of specialised tests (such 
as PET-CT), and were interpreted by local consultant 
radiologists as per usual clinical practice. Interpretation 
of standard investigations was masked to WB-MRI 
images and findings. Although UK NICE guidelines 
recommend staging chest abdomen and pelvic CT, and 
pelvis MRI in the case of rectal cancer4, case report forms 
included the nature and date of all standard investigations 
actually done before the first major treatment decision, 
and their findings regarding presence and location of any 
metastatic disease.
The platform used for WB-MRI was in line with usual 
practice. A minimum dataset of sequences was acquired, 
including diffusion, T2-weighted, and T1-weighted 
(pre-intravenous and post-intravenous gadolinium con-
taining contrast medium) imaging (appendix p 3). 
WB-MRI datasets were uploaded electronically to a secure 
central imaging server (3Dnet; Biotronics3D, London, 
UK) for interpretation, and were withheld initially from 
the local Picture Archiving and Communications System 
to ensure local radiologists interpreting standard staging 
investigations were masked.
Across all recruitment sites and imaging hubs, 
19 radiologists interpreted WB-MRI and were unaware of 
all other standard staging investigations and clinical 
information (other than the suspected cancer diagnosis 
and its segmental location). All radiologists were fellows 
of the Royal College of Radiologists and had interpreted at 
least 20 validated staging WB-MRIs. Radiologists with 
experience of fewer than 100 WB-MRI datasets initially 
had their reports validated by more experienced 
colleagues (ie, those who had worked on >100 WB-MRI 
datasets) and reported alone only once deemed competent 
by their colleague. This procedure was designed 
specifically to mirror how WB-MRI would be reported in 
NHS practice if more widely disseminated. Radiologists 
completed case report forms documenting the T and 
N stage of the local tumour (as per TNM 7th edition23), 
and the presence, location, and diameter of metastatic 
disease across various anatomical sites using six 
numerical confidence levels grouped subsequently into 
normal, equivocal, and abnormal. Radiologists interpreted 
WB-MRI as per their usual practice, considering known 
morphology and characteristics of metastatic disease 
across the various MRI sequences,24 and reproduced case 
report form findings in a free text clinical report, uploaded 
onto the 3Dnet software for subsequent release to the 
multi disciplinary team meeting. If additional tests were 
recommended for equivocal findings, this suggestion was 
included in their report.
Patients were discussed in the multidisciplinary team 
meeting at their local hospital as per usual care pathways. 
WB-MRI images and reports were withheld until patients 
had completed all standard staging investigations so that 
the multidisciplinary team made its first major treatment 
decision based only on standard staging.20 The decision 
was documented (appendix p 4), along with the TNM 
stage assigned. In the same meeting, the WB-MRI report 
and images were then shown to the multidisciplinary 
team via 3Dnet. The team considered the report and 
images and stated whether additional tests would have 
been requested before the first major treatment decision 
could be reached, had WB-MRI been the initial staging 
investigation (eg, to investigate equivocal findings). Any 
such tests were then done if they or an equivalent test had 
not already been done as part of the standard pathway and 
the multidisciplinary team considered them essential to 
patient care. If done already, their results were noted. The 
team recorded the TNM stage based on the WB-MRI 
staging pathway (ie, WB-MRI plus the results of any 
additional tests generated, if any) and stated what the first 
major treatment decision would have been on the basis of 
this pathway. The final multidisciplinary team treatment 
decision was then made based on all available tests 
(ie, standard pathway, WB-MRI, and any additional tests; 
appendix p 4).
We devised a reference standard using multidisciplinary 
consensus panel review, a procedure that is standard for 
diagnostic test accuracy studies where an independent 
reference standard does not exist or is impossible 
because of incorporation bias.20,25 Patients were followed 
up for 12 months (or until death, if sooner). Each 
recruitment site convened a series of panels to derive the 
For the protocol see https://
www.ctc.ucl.ac.uk/TrialDetails.
aspx?Trial=90&TherA=7
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reference standard TNM stage, consisting of at least two 
radiologists (one external to the site) with expertise in 
cross-sectional imaging and nuclear medicine, and an 
oncologist or colorectal surgeon, or both. The panel had 
access to a histo pathologist if required, and a member of 
the Cancer Research UK and University College London 
Cancer Trials Centre and trial management group 
attended to ensure the consensus process was uniform 
across the trial. The panel considered all available clinical 
data over the follow-up period, including images and 
results of all staging and follow-up investigations, 
surgical findings, histopathology (surgical resections and 
biopsies), and patients’ clinical course, and assigned a 
TNM stage for the time of recruitment. The location and 
size of any metastatic deposits were recorded. In the 
absence of histological proof, metastatic disease was 
assumed if new lesions appeared during follow-up with 
suggestive imaging characteristics, or if compatible 
lesions that were already present either progressed or 
responded to therapy. Specific criteria were applied 
depending on length of follow up (in the case of death) 
and if the primary tumour remained in situ (appendix p 5). 
From all follow-up data, the panel assigned a retrospective 
optimal primary treatment decision, noting radiological 
perceptual errors in the initial interpretation of staging 
investigations (ie, unreported metastases that could be 
identified by the panel in retrospect, with full knowledge 
of all follow-up investigations).
Outcomes
The primary outcome was the difference in per-patient 
sensitivity for metastatic disease detection between 
standard and WB-MRI staging pathways, compared 
against the consensus reference standard. Prespecified 
outcomes were reported according to the diameter of the 
largest metastatic deposit (≥1 cm or <1 cm) to assess the 
effect of lesion size on diagnostic accuracy, per-organ 
sensitivity, and for WB-MRI as a stand-alone investigation 
based on the original radiologist report.
Secondary outcomes were difference in per-patient 
specificity for metastatic disease detection between 
standard and WB-MRI staging pathways, agreement 
between treatment decisions based on alternate pathways 
and the multidisciplinary team and consensus panel 
treatment decisions, staging efficiency (time taken, test 
number, and costs), per-organ sensitivity and specificity 
Figure 1: Trial profile
WB-MRI=whole-body MRI.
1020 patients screened
370 recruited
299 assigned to pathway
650 excluded
91 refused extra visit
77 refused WB-MRI scan
70 patients felt inclusion in the trial
would delay potential treatment 
66 contraindications to WB-MRI
65 polyp cancer
37 no WB-MRI slot available within 
3 weeks of final staging
31 evidence of severe or uncontrolled
systematic disease
31 did not have primary colorectal cancer
24 too frail or not fit enough
22 psychiatric or other condition
14 language barrier
122 other
71 withdrawals
45 did not undergo WB-MRI
18 non-primary colorectal cancer diagnosis
3 withdrew consent
3 lost to follow-up
1 not enough data to assign stage
1 no consensus due to administrative 
error
WB-MRI pathway
299 had WB-MRI, plus additional tests as required
Standard pathway
299 had CT, plus additional tests as required
Reference standard 
299 included in consensus panel at 12 months
Value
Sex
Male 193 (65%)
Female 106 (35%)
Age, years
Median (IQR) 65 (57–71)
Range 30–90
Performance status
Fully active 199 (67%)
Ambulatory
Able to work 31 (10%)
Not able to work 3 (1%)
Not recorded 66 (22%)
Tumour location*
Rectum 130 (43%)
Sigmoid 86 (29%)
Descending 11 (4%)
Transverse† 24 (8%)
Ascending 29 (10%)
Caecum 43 (14%)
Data are n (%) unless otherwise stated. *By consensus reference standard. Some 
patients have multiple tumour locations. †Flexure tumours were combined and 
categorised as transverse colon.
Table 1: Baseline characteristics of final trial cohort
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for metastases, and per-patient agreement for local T and 
N stage. Additional secondary outcomes related to the 
effect of differing combinations of MRI sequences on 
accuracy, interobserver variability in WB-MRI inter-
pretation, and the effect of adding WB-MRI to standard 
pathways, and will be reported elsewhere. The 
comparative patient experience of staging pathways and 
the findings of a discrete choice experiment have already 
been reported.26–28
Statistical analysis
Using methods for comparative studies,29 we estimated 
that 290 patients would give 80% power to detect a 
clinically meaningful sensitivity difference of 10% between 
WB-MRI (85%) and standard pathways (75%), assuming 
40% metastatic prevalence, 73% concordance between 
pathways, and 10% withdrawal rate at 1 year, giving a 
target sample size of 322 patients. The observed with-
drawal rate was 19%; therefore, on Dec 7, 2015, as 
recommended by the independent data monitoring 
committee, the target sample size was revised to 
360 patients to ensure about 290 patients were evaluable.
We report our prespecified primary and secondary 
outcomes, and additional sensitivity analyses. Binary 
comparisons (sensitivity, specificity, and treatment 
decision agreement) were calculated using paired 
proportions (population marginal) in STATA 14.2 
(College Station, TX, USA). For the primary outcome, 
equivocal disease was considered positive for colon 
cancer and negative for rectal cancer, as specified by the 
independent data monitoring committee. Sensitivity 
analysis treated equivocal results as either negative or 
positive (additional analysis).
There were no missing data for the primary outcome. 
Statistical significance was determined on the basis of 
95% CIs from Newcombe paired proportion method;30 
McNemar’s test p values are reported. Pathway treatment 
decisions were grouped for analysis (appendix p 6) and 
compared to the final treatment decisions made by the 
multidisciplinary team and consensus panel (as a 
sensitivity analysis). Extra post-hoc analysis presented the 
primary tumour site divided into rectum and colon. 
Time to complete staging pathways (excluding initial 
diagnostic tests) was calculated in days, by adding times 
for staging tests (from request to performance) to median 
wait times for a treatment decision by the multidisciplinary 
team, calculated across all patients. In the case of missing 
data, median times from the same or similar tests were 
used. The median difference in time and number of 
staging tests between pathways was compared for each 
patient with 95% CI from 2·5 and 97·5 centiles of 1999 
bootstrap samples, with replacement used to compare 
between standard and WB-MRI staging pathways. 
Descriptive analysis of time to complete staging are 
reported in median days with IQR for staging pathways.
We compared the costs of WB-MRI versus standard 
pathways (appendix p 7). The cost analysis was based on a 
UK NHS perspective. Costs were calculated in pounds 
sterling (as of 2016–17) and were inflated as necessary. The 
time horizon was the time from initial diagnosis to 
treatment decision by the multidisciplinary team. Given 
the time horizon, which was less than 1 year, discounting 
was not applied. We calculated the mean cost per patient of 
tests received when undergoing standard imaging 
pathways only and WB-MRI (including additional staging 
tests ordered after the WB-MRI). We only included the cost 
of the tests received; the costs of the multidisciplinary 
team were not included because this cost was incurred 
irrespective of the type of staging test received. We did not 
include any adverse events related to imaging because no 
such events were reported. Unit costs were taken from 
2016–17 NHS reference costs.31 Decisions about which 
reference costs to use were made with appropriate clinical 
input (appendix p 8). Mean per-patient staging costs for 
standard pathways and WB-MRI were compared using 
95% CIs derived from 1000 bootstrapped replications of 
the mean with replacement
Streamline C is registered with the International 
Standard Randomised Controlled Trial registry, number 
ISRCTN43958015.
Role of the funding source
The funder of the study stipulated that the study design 
should be a diagnostic accuracy trial using a cohort 
Patients with 
metastatic 
disease*
Sensitivity Patients 
without 
metastatic 
disease*
Specificity
WB-MRI staging 
pathway†
Standard 
staging pathway
Difference p value WB-MRI staging 
pathway†
Standard 
staging pathway
Difference p value
Diagnostic accuracy‡ 68 67% (56 to 78) 63% (51 to 74) 4% (–5 to 13) 0·51 231 95% (92 to 97) 93% (90 to 96) 2% (–2 to 6) 0·48
Equivocal lesions 
considered positive
68 71% (59 to 80) 68% (56 to 78) 3% (–6 to 12) ·· 231 95% (91 to 97) 92% (88 to 95) 3% (–2 to 7) ··
Equivocal lesions 
considered negative
68 65% (53 to 75) 58% (46 to 68) 7% (–2 to 17) ·· 231 98% (94 to 99) 98% (95 to 99) 0% (–3 to 2) ··
Data are n or % (95% CI). *Patients by consensus reference standard. †WB-MRI plus additional generated tests. ‡Equivocal results considered positive for colonic tumours and negative for rectal tumours.
Table 2: Per-patient sensitivity and specificity for metastatic disease
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design, but was not involved in data collection, data 
analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between March 26, 2013, and Aug 19, 2016, 1020 patients 
were screened for eligibility (figure 1). 370 patients were 
recruited, of which 71 were excluded. The final cohort of 
299 patients had a median age of 65 years (IQR 57–71) 
and 106 (35%) were women (figure 1, table 1). According 
to the consensus reference standard, 288 (96%) patients 
were stage T2 or above, 166 (56%) were node-positive 
(appendix p 9), and 68 (23%) had metastatic disease at the 
time of staging (48 [71%] of 68 had liver metastasis; 
appendix p 10). In six patients with metastatic disease at 
the time of staging (according to protocol definitions; 
appendix p 5), metastasis only became apparent during 
follow-up and was not visible on initial staging 
investigations, even in retrospect.
Sensitivity of staging for patients with metastatic 
disease was 67% (95% CI 56–78) for WB-MRI and 
63% (51–74) for standard pathways, a difference of 4% 
(–5 to 13, p=0·51; table 2, figure 2). For the primary 
outcome, there were three perceptual errors in the 
WB-MRI pathway and six in the standard pathway. No 
adverse events (serious or non-serious) were reported 
during the trial.
Specificity did not differ between the WB-MRI pathway 
(95% [95% CI 92–97]) and standard pathway (93% 
[90–96], p=0·48). Sensitivity analysis found no significant 
differences between pathways when lesions reported as 
equivocal were treated as either all positive or all negative 
(table 2), or across individual organ sites (appendix p 11). 
The WB-MRI pathway had 86% (95% CI 74–94) sensitivity 
for patients whose largest metastasis was at least 1 cm, 
which did not differ from standard pathways (82% [69–91]; 
appendix p 12). As a stand-alone investigation (ie, without 
additional tests generated) WB-MRI had a similar 
sensitivity to that of the standard pathway, but had lower 
specificity than the standard pathway (appendix p 13).
The WB-MRI pathway had 54% agreement for T stage 
compared with 60% for the standard pathway, a non-
significant difference of 6% (95% CI 0–12; appendix p 14). 
N stage agreement did not significantly differ between 
the pathways (appendix p 15). Agreement with the final 
treatment decision of the multidisciplinary team was 96% 
for WB-MRI and 95% for the standard pathway (table 3). 
Treatment decisions based on WB-MRI and standard 
pathways had similar levels of agreement with the 
retrospective consensus panel optimal treatment decision 
for rectal and non-rectal cancers (appendix p 16).
Across the cohort, standard staging pathways involved 
558 individual investigations and WB-MRI involved 
320 individual investigations; WB-MRI pathways 
generated an additional 21 tests (appendix pp 17–18). 
WB-MRI pathways required fewer tests (median, 
one [95% CI 1 to 1]) than did standard pathways 
(two [2 to 2]), a difference of one (1 to 1; appendix p 19).
Time to staging was shorter for WB-MRI pathways 
than for standard pathways (median, 8 days [IQR 6–9] vs 
13 days [11–15]); a difference of 5 days (3–7; figure 3, 
appendix pp 20–21). Mean per-patient costs for the 
WB-MRI pathway (£216 [95% CI 211–221]) were lower 
than for the standard staging pathway (£285 [260–310]; 
appendix p 22).
Discussion
To date, Streamline C is the largest prospective, multi-
centre trial to compare the diagnostic accuracy of 
WB-MRI and standard staging pathways for metastatic 
disease in patients newly diagnosed with colorectal 
cancer. Both pathways showed similar accuracy, but the 
n* WB-MRI staging pathway† Standard staging pathway Difference 
agreement, % 
(95% CI)
Agreement Disagreement Agreement Disagreement
Colorectal cancer
All patients 296 284 (96%) 12 (4%) 282 (95%) 14 (5%) 1% (–2 to 4)
Colon cancer
All patients 168 166 (99%) 2 (1%) 165 (98%) 3 (2%) 1% (–3 to 4)
Patients with 
metastatic disease
33 33 (100%) 0 (0%) 32 (97%) 1 (3%) 3% (–6 to 12)
Patients without 
metastatic disease
135 133 (99%) 2 (1%) 133 (99%) 2 (1%) 0% (–4 to 4)
Rectal cancer
All patients 128 118 (92%) 10 (8%) 117 (91%) 11 (9%) 1% (–5 to 7)
Patients with 
metastatic disease
32 28 (88%) 4 (12%) 28 (88%) 4 (12%) 0% (–10 to 10)
Patients without 
metastatic disease
96 90 (94%) 6 (6%) 89 (93%) 7 (7%) 1% (–7 to 9)
Data are n (%) unless otherwise stated. *Three patients were missing at least one type of patient treatment decision. 
†WB-MRI plus additional generated tests.
Table 3: Agreement between pathway and multidisciplinary team treatment decisions
Figure 2: WB-MRI and standard staging pathways sensitivity and specificity for patients with metastatic 
disease against the consensus reference standard
WB-MRI=whole-body MRI.
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WB-MRI pathway was more time-efficient and cost-
efficient. Treatment decisions were similar. Our data 
suggest WB-MRI is a viable and desirable replacement 
for standard pathways.
WB-MRI pathways had no advantage over standard 
pathways in terms of diagnostic accuracy. The overall 
sensitivity of WB-MRI pathways (and WB-MRI alone) for 
metastatic disease was lower than published meta-
analyses suggest. For example, Xu and colleagues7 
reported per-patient sensitivity and specificity of WB-MRI 
as 86% (95% CI 70–94) and 97% (94–99), respectively, in 
a meta-analysis of nine studies. However, primary studies 
considered a wide range of primary cancers, were single-
site explanatory studies, and all except one recruited 
fewer than 150 patients. The largest previous study19 of 
WB-MRI for colorectal cancer staging recruited just 
20 patients. Our consensus reference standard con-
sidered a follow-up of 12 months and several patients 
showed metastases during this period that were not 
visible, even in retrospect, on any imaging modality. 
Such disease is currently beyond the resolution of cross-
sectional imaging and, in part, explains the large number 
of patients who relapse after attempted curative resection. 
The number of perceptual errors was low, and many 
retrospectively visible lesions were subtle and difficult to 
detect prospectively. As a pragmatic trial, Streamline C 
provides the best estimate of colorectal cancer staging 
accuracy in routine clinical practice.
We found that the WB-MRI pathway had 86% sensitivity 
for patients with metastatic disease of at least 1 cm. 
48 (71%) of 68 patients with metastasis had liver 
metastasis, and the association between diameter and 
detection is well established. In their 2010 meta-analysis, 
Niekel and colleagues32 reported that sensitivity of even 
dedicated liver MRI is often below 50% for liver 
metastases that are less than 1 cm. It is important to 
differentiate WB-MRI staging protocols from those 
intended specifically to stage the liver. Our WB-MRI 
protocol complied with accepted international standards, 
including diffusion weighted imaging and post-
gadolinium sequences; however, by necessity, we had to 
compromise—for example, on slice thickness—to ensure 
reasonable total scan times. Although the addition of 
liver-specific contrast agents to standard protocols is 
feasible and will probably improve sensitivity, costs might 
be prohibitive in some health-care settings.
We found that WB-MRI pathways had similar accuracy 
for T and N staging compared with standard pathways. 
Although MRI appears to be promising for local staging 
of colorectal cancer, its superiority over CT is unproven.33 
Agreement with both the final multidisciplinary team 
treatment decision and the optimal retrospective treat-
ment decision was similar for both staging pathways, 
suggesting that WB-MRI could replace standard path-
ways without patient detriment.
Generally, efficiency receives less attention than 
diagnostic accuracy.21 Streamline C found that WB-MRI 
pathways were more efficient than standard pathways, 
substantially reducing the number of tests needed and 
time to complete staging. These changes affected costs, 
with average per-patient staging costs decreasing by £69. 
Although it is unlikely that shortening staging time by a 
few days will directly affect patient outcomes, prolonged 
pathways increase anxiety so any reduction is advan-
tageous.6 Although access to MRI is restricted in many 
health-care settings, our data suggest that increased 
provision would ultimately reduce the cost and 
complexity of staging colorectal cancer. A discrete choice 
experiment done as part of the trial shows patients 
generally prefer WB-MRI staging to standard pathways, 
if they reduce staging test number, staging times, and 
radiation exposure as found in Streamline C.28
A strength of our trial is its pragmatic design. We 
recruited from a representative range of general and 
teaching hospitals, with all imaging done and interpreted 
according to usual local protocols, to increase gener-
alisability of our results. The 19 radiologists interpreting 
WB-MRI were representative of those who would do so 
in daily NHS practice. We avoided using a smaller 
number of highly experienced radiologists; although we 
acknowledge that such individuals might achieve 
sensitivities greater than we report, they do not represent 
the national workforce. We used multidisciplinary team 
meetings to mirror patient care in the NHS. In doing so, 
we captured the entirety of standard pathways, including 
contemporaneous treatment decisions. We used a novel 
cloud-based image repository to maintain blinding and 
control multidisciplinary team access to WB-MRI until 
the appropriate time in the decision-making process. We 
were able to model the content and timing of WB-MRI 
staging pathways, and the potential effect on decision 
making. Conversely, previous research usually reports 
head-to-head comparisons between single imaging 
platforms, failing to capture pathway complexity. To our 
knowledge, our trial design is unique.
Streamline C does have limitations. We masked 
radiologists to patient history and, for WB-MRI, to 
Figure 3: Time taken for staging pathways
WB-MRI=whole-body MRI.
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contemporaneous imaging, which was necessary to 
isolate diagnostic test accuracy within a pragmatic setting. 
Participants were representative of those under going 
staging in daily practice, although we did exclude pregnant 
women, patients not wanting to undergo WB-MRI, and 
patients with contraindications to MRI. The prevalence of 
metastatic disease was lower than assumed by our power 
calculation. However, the independent data monitoring 
committee recommended continuing the trial so as to 
achieve our original target number of evaluable patients. 
On independent data monitoring committee advice, 
equivocal findings were treated as negative for rectal 
cancer (as many undergo chemoradiation, allowing such 
lesions to be characterised over time). Sensitivity analysis 
found that alternate classification of equivocal abnorm-
alities had no meaningful effect. We modelled timing of 
WB-MRI staging pathways on the basis of real waiting 
times collated from recruitment sites during the trial, 
although sites had capacity to do WB-MRI. Waiting times 
might not be representative of those at other hospitals, 
and in other countries. Some of the benefits of reduced 
staging time by WB-MRI pathways could be negated if 
time to commencing treatment (eg, surgical resection) are 
not reduced in parallel. Treatment decisions based on 
WB-MRI pathways were made after the multidisciplinary 
team was unmasked to all standard imaging tests, which 
could introduce bias. However, this situation was 
unavoidable if the full complexity of standard staging 
pathways was to be captured without interference from 
WB-MRI findings and if treatment decisions were to be 
recorded contemporaneously. Furthermore, alternate 
pathway agreement with a retrospective optimal treatment 
at 12 months remained very similar. Our cost analyses 
reflect an English NHS perspective and could differ in 
other settings, which might negate some of the cost 
advantages of WB-MRI pathways. Although WB-MRI is 
advocated as being safer than current standard staging 
investigations, new technologies are reducing radiation 
dose,34 and there are current uncertainties about the 
neuronal deposition of gadolinium.35 Further research is 
needed to define the potential use of WB-MRI in the 
assessment of treatment response and post-therapy 
surveillance for recurrent disease. Our findings are 
specific to colorectal cancer and might not be relevant to 
other primary tumour sites.
In summary, WB-MRI staging pathways have similar 
diagnostic accuracy to standard pathways for identifying 
patients with metastatic disease in newly diagnosed 
colorectal cancer, and precipitate similar treatment 
decisions. However, they reduce staging time, test number, 
and costs. In a real-world NHS setting, WB-MRI-based 
pathways are a viable replacement for standard pathways.
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